Company Description
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform.
The company’s lead infectious disease product candidate is HB-200 for the treatment of pembrolizumab which is in Phase 2 of clinical trial; HB-700, a preclinical development for treatment of KRAS mutated cancers, including lung, colorectal, and pancreatic cancers.
Its lead product candidates are HB-400 for the treatment of Hepatitis B which is in Phase I of clinical trial and HB-500 for the treatment of HIV which is in Phase I of clinical trial.
The company’s preclinical stage products include HB-300 program for prostate cancer. It has a collaboration with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products using or incorporating its replicating and non-replicating technology platforms for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus.
HOOKIPA Pharma Inc. was incorporated in 2011 and is headquartered in New York, New York.
Country | United States |
Founded | 2011 |
IPO Date | Apr 18, 2019 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 179 |
CEO | Malte Peters |
Contact Details
Address: 350 Fifth Avenue, 72nd Floor New York, New York 10118 United States | |
Phone | 431 890 6360 |
Website | hookipapharma.com |
Stock Details
Ticker Symbol | HOOK |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
IPO Price | $14.00 |
CIK Code | 0001760542 |
CUSIP Number | 43906K100 |
ISIN Number | US43906K1007 |
Employer ID | 81-5395687 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. Malte Peters M.D. | Chief Executive Officer and Director |
Mary Theresa Coelho M.B.A. | Executive Vice President, Chief Financial Officer and Director |
Prof. Rolf M. Zinkernagel M.D., Ph.D. | Co-Founder |
Andreas Bergthaler | Co-Founder |
Lukas Flatz | Co-Founder |
Dr. Roman Necina Ph.D. | Chief Operations Officer |
Dr. Klaus Orlinger Ph.D. | Chief Scientific Officer |
Matthew L. S. Beck | Executive Director of Investor Relations |
Michael Szumera | Executive Director of Communications |
Dr. Mark Winderlich Ph.D. | Chief Research and Development Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Aug 30, 2024 | 8-K | Current Report |
Aug 8, 2024 | 424B5 | Filing |
Aug 8, 2024 | 10-Q | Quarterly Report |
Aug 8, 2024 | 8-K | Current Report |
Aug 2, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Jul 26, 2024 | 8-K | Current Report |
Jul 10, 2024 | 8-K | Current Report |
Jul 8, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
Jun 18, 2024 | 8-K | Current Report |
Jun 14, 2024 | SC 13D | General statement of acquisition of beneficial ownership |